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Abstract
Background: Accurate determination of neutralization antibody titers supports epidemiological studies of dengue virus
transmission and vaccine trials. Neutralization titers measured using the plaque reduction neutralization test (PRNT) are
believed to provide a key measure of immunity to dengue viruses, however, the assay’s variability is poorly understood,
making it difficult to interpret the significance of any assay reading. In addition there is limited standardization of the
neutralization evaluation point or statistical model used to estimate titers across laboratories, with little understanding of
the optimum approach.
Methodology/Principal Findings: We used repeated assays on the same two pools of serum using five different viruses
(2,319 assays) to characterize the variability in the technique under identical experimental conditions. We also assessed the
performance of multiple statistical models to interpolate continuous values of neutralization titer from discrete
measurements from serial dilutions. We found that the variance in plaque reductions for individual dilutions was 0.016,
equivalent to a 95% confidence interval of 0.45–0.95 for an observed plaque reduction of 0.7. We identified PRNT75 as the
optimum evaluation point with a variance of 0.025 (log10 scale), indicating a titer reading of 1:500 had 95% confidence
intervals of 1:240–1:1000 (2.7060.31 on a log10 scale). The choice of statistical model was not important for the calculation
of relative titers, however, cloglog regression out-performed alternatives where absolute titers are of interest. Finally, we
estimated that only 0.7% of assays would falsely detect a four-fold difference in titers between acute and convalescent sera
where no true difference exists.
Conclusions: Estimating and reporting assay uncertainty will aid the interpretation of individual titers. Laboratories should
perform a small number of repeat assays to generate their own variability estimates. These could be used to calculate
confidence intervals for all reported titers and allow benchmarking of assay performance.
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Introduction
Dengue remains a substantial public health problem in tropical
and subtropical regions [1]. All four serotypes of the mosquito-
borne virus are capable of producing significant morbidity and
death [2]. As part of efforts to monitor and control the disease,
public health agencies and vaccine developers use serological
methods to perform surveillance and assess vaccine trial outcomes.
A standard for characterizing serotype-specific neutralizing
dengue antibody levels is the Plaque Reduction Neutralization
Test (PRNT) [3]. PRNT readouts are known to vary substantially,
even on samples from the same individual, however, the extent of
the underlying variability in estimates remains unclear [4]. There
are many potential sources of variation including within experi-
ment and between experiment sources. In addition, different
laboratories use different cell lines, different viral strains with
varying viral passage number, and parametric models to calculate
PRNT with the impact of the alternative approaches
poorly understood [5–7]. Laboratories also use PRNT evaluation
points that range between PRNT50 to PRNT90, and may perform
varying numbers of serial dilutions [6,8–10]. Understanding and
characterizing the variability of the assay may greatly increase the
accuracy and quantifiability of the assay, important both in
epidemiological and vaccine studies.
After infection by one of the four dengue virus serotypes,
individuals develop antibodies against the infecting virus [2]. The
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PRNT assay is used to measure neutralizing antibodies produced
in response to this exposure. When an in vitro monolayer of cells is
exposed to the virus without the presence of neutralizing
antibodies, the viral particles enter and kill the cells. Where viral
particles have spread between neighboring cells, a ‘plaque’ of dead
cells is created that can be observed and counted. The presence of
neutralizing antibodies from an individual’s serum reduces the
number of plaques formed by inhibiting the virus. In most cases,
for a given concentration of antibodies, the addition of lower
dilutions of serum result in fewer plaques formed than higher
serum dilutions. PRNT50 is the estimated serum dilution that
produces a 50% reduction in the number of plaques formed
compared to the number formed on monolayers in the absence of
antibody [3]. PRNT50 is believed to give an indication of an
individual’s ability to neutralize the dengue virus if exposed in vivo
and to indicate whether an individual has been exposed in the
past.
Absolute titer estimates from a single serum sample are used in
vaccine studies as a potential marker of protection following
immunization [11,12]. In addition, epidemiological cohort studies
may estimate the risk of serotype-specific disease by absolute titer
at baseline [13]. Comparisons between titers from two samples
taken from the same individual are also routinely undertaken. For
example, four-fold differences in titers from acute and convales-
cent sera are typically taken to signify seroconversion [14]. Cohort
studies also use large serotype-specific titer differences between
study visits as evidence of infection, allowing the detection of
asymptomatic infections that cannot be identified through
symptomatic disease surveillance [15].
An individual’s ability to successfully neutralize a strain of
dengue may depend on the age of the individual, gender,
nutrition, genetic factors as well as the history and time of
previous infections by other flaviviruses [2,16]. In comparing
single PRNT estimates between individuals, it is not possible to
separate differences due to these host factors from differences due
to assay variability. Understanding the variability of the assay
instead requires a large number of repeated experiments on the
same serum. This necessitates large pools of serum that are rarely
available. However, as part of each experiment, laboratories often
use high titer and low titer serum controls to ensure consistency of
experimental conditions between assays. Control sera lots can
come from pooled human sera that are maintained and remain
unchanged for several years. In each experiment, PRNTs are
calculated for each control serum (as well as the test serum under
investigation). Using the plaque counts from the control sera from
a large number of assays, we can estimate the variability in the
PRNT within identical experiments.
Methods
The Armed Forces Research Institute of Medical Sciences
(AFRIMS) in Bangkok, Thailand developed the dengue PRNT
assay in the 1960s and has been performing it since for surveillance
of dengue immunity in the population and supporting vaccine
trials and cohort studies [3,4,13,17]. Data for the current study
comes from control assays of PRNTs performed at AFRIMS
between 2007 and 2013. Briefly, in each assay, a monolayer of
continuous Macaca mulatta kidney cells (LLC-MK2) was infected
with virus, predetermined to be in the range of 30–50 plaque-
forming units in the presence of 4-fold serial dilutions of heat-
inactivated serum (range of 1:10 to 1:163840). The well for each
dilution was 4.5 cm2 in size (12 wells per plate). For each dilution,
the number of viral plaques was counted and compared to the
number of plaques in a control where no serum was added. Each
dilution and control was performed in duplicate. During the study
period there were changes to the number and cell lines used to
passage the virus, and the number of passages that the virus went
through. In addition, the DENV-4 viral strain was changed in
2009 (Table 1). Three technicians conducted over 95% of all
assays in the study period.
Serum pools
Two serum pools (a high titer and a low titer pool) were
collected and created in 2006 and used throughout the study
period. The high titer pool was obtained by pooling residual blood
samples from multiple Thai individuals that tested positive for
dengue virus using IgG ELISA. A portion of the pool was then
diluted with human sera from PRNT-negative blood donors to
create a low titer pool.
Viruses
Five viruses were used during the study period, one each for
DENV-1, DENV-2 and DENV-3 and two for DENV-4 (Table 1).
Around every two years, viral stocks were generated in batches by
passaging virus through C6/36 mosquito cell lines (between one
and eight passages) and up to three passages in either suckling
mice (SM) or LLC-MK2 cells.
PRNT calculation
Basic regressions were used to interpolate the titer at which
defined reductions (PRNT ‘‘evaluation points’’) occur from the
observed reductions (e.g., a 50% reduction for a PRNT evaluation
point of PRNT50). We calculated PRNTs over the range PRNT40
to PRNT90 using either (a) probit regression, (b) logistic regression,
(c) complementary log-log (cloglog) regression or (d) four-
parameter non-linear regression [8]. To explore the reduction in
variance from repeat dilutions, PRNTs were calculated using both
individual set of dilutions and by using the average plaque
reductions across repeat dilutions.
As PRNTs can be resource intensive, laboratories may perform
two dilutions that they expect will contain the PRNT evaluation
point of interest and use straight line interpolation on the log-
transformed dilutions [6]. To estimate the variability of this
approach, we initially identified the expected PRNT titer using all
assays from a viral strain and serum pool and identified the two
sequential dilutions that contained this value. For each experiment
Author Summary
Plaque Reduction Neutralization Tests (PRNTs) remain the
most popular approach to characterize an individual’s
ability to neutralize dengue viruses and are widely used in
both epidemiological studies and vaccine trials. However,
the underlying variability in the assay is poorly understood,
hindering the interpretation of PRNT titer estimates.
Further, there is little standardization of its use across
laboratories limiting our ability to compare results across
settings. Here we used many repeated experiments on the
same serum under identical laboratory conditions to
estimate the variance in titer measurements. We also
identified both the optimum PRNT evaluation point and
statistical model to calculate titers. By providing an
estimate of the variability in the assay, laboratories will
be able to provide a confidence bound on individual PRNT
readings. In addition by providing recommended statistical
approaches that could be used across laboratories, our
findings will help the standardization of the assay across
settings.
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we then only used the values from the two sequential dilutions to
calculate PRNT using straight-line interpolation. We did not
calculate PRNTs in experiments where the two dilutions did not
contain the PRNT evaluation point of interest.
Finally, some laboratories perform Single Dilution Neutralization
Tests (SDNTs) to identify exposure using a single dilution [18,19].
The test is scored as positive if greater than 70% plaque reduction is
observed (using one or more reference dengue viruses) at a 1:30
dilution, although the optimal plaque reduction or dilution remains
unclear [18,19]. To provide insight into the risk of incorrectly
categorizing individuals as positive or negative, we calculated the
variance in the neutralization proportions for all experiments from
each individual dilution for each viral strain and serum pool.
Bias and mean squared error
We assumed that the ability of each of the two serum pools to
neutralize a particular viral strain was constant within any year,
reflected in a single ‘true’ PRNT titer for each virus for both the
high titer and the lower titer pools (i.e., one for each row in
Table 1). We considered PRNT estimates from a flexible non-
parametric spline, fitted to the plaque reductions from all
experiments within each year from a single serum pool as the
best, unbiased estimate of the ‘true’ PRNT for that pool.
We explored whether there existed any systematic differences
(bias) in PRNT estimates calculated using the different models. For
each experiment, we calculated PRNT titers using each of the
models (probit, logit, cloglog regression and non-linear regression).
Bias was suggested when there was a systematic difference between
the PRNT estimates using the model and the estimate of the ‘true’
titer. In addition we calculated the mean squared error (MSE) in
the estimates. We reported an average MSE, bias and variance for
each PRNT evaluation point and model, weighted by the number
of experiments using each virus and serum pool. We used
bootstrapping to generate 95% confidence intervals for the bias,
variance and MSE estimates from each PRNT evaluation point
and model. Over 1,000 resamples, we recalculated the bias,
variance and MSE of the assays. Ninety-five per cent confidence
intervals were calculated from the 2.5% and 97.5% quantiles from
the resultant distributions. Finally, to explore whether time
difference between assays was associated with observed variability,
we estimated the variance in titers for assays performed across
different time periods.
Plate-specific versus non-plate-specific sources of
variance
We can divide variability in titers into ‘plate-specific’ and ‘non-
plate- specific’ sources of variance, where ‘plate-specific’ is taken to
mean experimental factors that are identical in assays performed
on the same plate. In particular this will include the preparation of
diluted virus solution that is added to wells on the same plate (a
new viral solution is made for each separate plate). Non-plate-
specific factors are all other sources of variability that will be
present across all assays, irrespective of whether they are
conducted on the same plate or not. This will include variability
in the ability of the serum to neutralize the virus and variability in
plaque counting. We estimated non-plate-specific variability by
calculating the variance in titer estimates across assays performed
on the same plate. Plate-specific variance was calculated by
subtracting the non-plate-specific variance from the total variance
in titers from assays performed on difference plates.
Absolute and relative titer measurements
Absolute antibody titers may be used as a marker of immunity.
More common, however, is the comparison of titers from
convalescent and acute sera taken from the same individual for
detection of seroconversion. Increasing the number of repeat
dilutions for each serum will reduce the uncertainty of both
absolute and relative titer estimates. Using our estimates of the
variability in the assay, we calculated the expected variance from
performing different numbers of repeat dilutions (varied between 0
and 3 repeats). We considered scenarios where repeated dilutions
were conducted on the same plate (and would therefore not reduce
plate-specific sources of variability) and where repeats were
conducted on different plates where both plate-specific and non-
plate-specific variance would decrease. In addition we used our
variance estimates to calculate the proportion of paired samples
that would result in a greater than four-fold difference in titers
where no true difference exists (i.e., a false positive result).
Multilevel model
Plaque density may be associated with differential levels of
plaque overlap, which would bias titer estimates. We can use the
number of plaques in the reference well (where no sera is added) as
a marker of plaque density. Heterogeneities in the passaging of the
virus may also be associated with changing PRNT estimates. To
Table 1. Number of experiments by serum pool and viral strain combination.
Serum Pool Neutralizing strain N (%), PRNT75
Serotype High/low titer Total = 2319
DENV- 1 High titer Thailand/16007/1964 288 (12) 1:5200
DENV- 1 Low titer Thailand/16007/1964 288 (12) 1:510
DENV- 2 High titer Thailand/16681/1984 279 (12) 1:6000
DENV- 2 Low titer Thailand/16681/1984 279 (12) 1:650
DENV- 3 High titer Philippines/16562/1964 285 (12) 1:3690
DENV- 3 Low titer Philippines/16562/1964 285 (12) 1:320
DENV- 4A High titer Indonesia/1036/1976 179 (8) 1:220
DENV- 4A Low titer Indonesia/1036/1976 180 (8) 1:20
DENV- 4B High titer Thailand/C0036/2006 128 (5) 1:1880
DENV- 4B Low titer Thailand/C0036/2006 128 (5) 1:190
The final column shows the PRNT75 calculated using a smooth spline from all experiments.
doi:10.1371/journal.pntd.0002952.t001
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quantify systematic differences in titer estimates by the number of
passages and the type of cell (C6/36, SM and LLC-MK2 cells),
plaque density and the age of the virus stock, we constructed a
multilevel model with a random intercept for each viral strain and
serum pool combination (listed in Table 1).
Ethics statement
All experiments were conducted using pooled residual sera from
public health service testing and, as per Walter Read Armed
Institute of Research (WRAIR) policy, did not require ethics
review. WRAIR is the parent organization of AFRIMS.
Detailed methods can be found in the supplementary materials.
Results
Between 2007 and 2013, a total of 2,319 assays were performed
using five different viruses on two different control sera (Table 1).
An average of 4.4 dilution steps were performed in each assay
(range: 3–5) with each dilution performed twice (20,286 individual
dilutions in all).
Plaque reduction variability
There existed substantial variability in the plaque reduction
proportions (Figure 1) with consistent variability in plaque
reductions for each dilution (Figure 2). On average, the variance
for an individual dilution performed on the same serum using the
same virus was 0.016, equivalent to a 95% confidence interval of
0.45–0.95 for an observed plaque reduction of 0.7. Performing a
repeated set of dilutions reduced the variance to 0.011, equivalent
Figure 1. Plaque reduction estimates for each experiment. Each black dot represents the mean reduction in plaques formed for that dilution
from two repeats. The red dots are the overall means across all the experiments. Superimposed are fitted models using a probit transformation, a
cloglog transformation and a non-parametric spline (the estimate of the ‘true’ titers).
doi:10.1371/journal.pntd.0002952.g001
Figure 2. Plaque reduction proportions for individual dilutions.
Each solid line represents the 2.5% and 97.5% quantiles of plaque
reductions from the average of two repeats from a single dilution from
a particular virus – serum pool combination. The shaded area represent
asymptotic 95% confidence intervals calculated from the overall
variance observed in the plaque reduction proportions.
doi:10.1371/journal.pntd.0002952.g002
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to a 95% confidence interval of 0.50–0.90 for the same observed
plaque reduction of 0.7.
Identifying the optimum PRNT model and PRNT
evaluation point
The variability in plaque reduction proportions led to hetero-
geneity in PRNT titer estimates. For each set of dilutions
performed on each serum and using each virus, we used four
different statistical models to calculate titers at PRNT evaluation
points varying from PRNT40 to PRNT90. In each case we
calculated the bias, variance and mean squared error in the
estimated titers. Four-parameter non-linear regression could only
be used on 63% of the assays, as the remaining assays had either
insufficient dilutions or the resultant curve fluctuated too much to
allow model fit (Table 2). All assays could be used for the other
statistical models. When comparing the models, we only used the
assays where estimates existed for all four approaches. We found
that the probit and logit models consistently over-estimated titers
(Figure 3A). For example, for a PRNT evaluation point of
PRNT50, the probit model overestimated the titer by an average of
0.14 (log10 scale) and logit by 0.12 (log10 scale). The cloglog and
four-parameter non-linear regression were largely unbiased. The
variance in titer estimates was very similar across models
(Figure 3B). However, the variance varied widely by PRNT
evaluation point. Variance was lowest at PRNT75 for the probit,
logit and four-parameter non-linear regression and lowest at
PRNT80 for the cloglog model. Overall, the lowest mean-squared
error existed from using the cloglog model at a PRNT evaluation
point of PRNT75 (Figure 3C).
Where only two dilutions were used, only 50% of the
experiments could be used as the two sequential dilutions did
not contain the PRNT evaluation point in the remainder and
would have required extrapolation. Where it could be estimated,
the standard deviation of PRNT50 using two dilutions was
estimated at 0.13 (log10 scale), however, this only represents the
variability of the subset of the experiments where the two dilutions
had reductions in plaques that were closest to the best estimate of
the unbiased PRNT and cannot be compared to the variability
observed in the other approaches.
Plate-specific versus non-plate-specific sources of
variance
To calculate the variance in non-plate-specific factors, we
calculated the variance in titers calculated from single sets of
dilutions performed on the same plate using a cloglog model and a
PRNT evaluation point of PRNT75 (the model and evaluation
point with the lowest mean squared error) from all assays. We
found a variance of 0.014 (log10 scale) for titer estimates calculated
on the same plate compared to a variance of 0.032 (log10 scale) for
titer estimates from different plates (all estimated from single sets of
dilutions). These findings indicate that the variance from non-
plate-specific factors was 0.014 (log10 scale) and the variance from
plate-specific factors was 0.018 (the difference in the two variance
estimates, log10 scale). We found no difference in the variance in
titers between assays by the time separation between them: titers
from assays performed within the same month were as variable as
from assays performed over a year apart (Figure S1). When a
single titer estimate was calculated from two sets of dilutions from
the same plate (i.e., the common practice of performing a repeat
set of dilutions on the same plate), the variance in titer estimates
was 0.025 (log10 scale). This is identical to what we would expect
from a reduction in non-plate-specific variance only (i.e., 0.018+
0.014/2). Had repeats been performed on different plates, we
estimate that the variance would have reduced further to 0.016
(i.e., 0.018/2+0.014/2, log10 scale) reflecting a reduction in both
non-plate-specific and plate-specific variance.
Laboratories may wish to calculate their own lab-specific
variability measures by performing repeated assays on the same
Figure 3. Estimates of (A) bias2, (B) variance and (C) mean
squared error in titers from a single set of dilutions by PRNT
evaluation point for the different models. Bias for each
experiment was calculated by comparing the model PRNT results with
that from a smooth spline from all experiments from that particular
virus and serum pool. Only assays where titers could be calculated for
all four models (63% of all assays) were used.
doi:10.1371/journal.pntd.0002952.g003
Table 2. Estimated standard deviation and bias in PRNT75 estimates using the different models.
Model Proportion of assays Variance (log10 scale) Bias (log10 scale)
[95% confidence interval]
Probit regression 100% 0.036 [0.030–0.040] 0.042 [0.035–0.049]
Logistic regression 100% 0.036 [0.030–0.040] 0.055 [0.049–0.063]
Cloglog regression 100% 0.025 [0.021–0.030] 0.027 [0.021–0.033]
Four-parameter non-linear regression 63% 0.022 [0.017–0.027] 0.059 [0.052–0.066]
Values are averages from the different viruses and serum pools, weighted by the number of experiments.
doi:10.1371/journal.pntd.0002952.t002
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serum. To estimate the number of assays laboratories would need
to perform to get a reliable variance estimate, we estimated the
precision in the variance estimate using different numbers of assays
(between 2 and 30) on the same serum using the same viral strain.
We found that with only 20 assays, the width of the 95%
confidence interval for the variance would be only 0.013, only
slightly higher than the width calculated from all samples (Figure
S2).
Absolute titer measurement
We found that the titers estimated for each of the ten virus-
serum pool combinations varied similarly (Figure 4B). Therefore a
single variance estimate appears appropriate when calculating
confidence intervals for a titer. We found that, for example, for a
titer estimate of 1:500 where no repeat dilutions have been
performed and the titer was estimated using a cloglog model with a
PRNT evaluation point of PRNT75, a 95% confidence interval
would be 1:200–1:1100 (2.7060.35 on a log10 scale). Performing a
repeated set of dilutions on the same plate (the most common
practice) results in a confidence interval of 1:240–1:1000
(2.7060.31 on a log10 scale). Finally, performing repeated
dilutions on a separate plate reduces the confidence intervals
further to 1:280–1:880 (2.7060.25 on a log10 scale). Note that
performing a single repeat on a different plate reduces the width of
the confidence intervals substantially greater than performing even
additional repeats on the same plate (Figure 4A). We tested the
coverage of our uncertainty estimates by calculating individual
confidence intervals for each assay (2,319 confidence intervals in
all). We found that 96% of these intervals contained the true titer
estimates, suggesting excellent coverage.
Relative titer measurements
Researchers are often interested in the ratio of titers between
acute and convalescent serum samples taken from the same sick
individual. We found that while the probit and logit models
produced substantially biased results, the extent of the bias did not
appear to differ by the magnitude of the titer (Figure S3).
Therefore, while individual PRNT estimates may be biased using
these models, ratios of PRNTs would not be as both the numerator
and the denominator would be similarly biased. As the different
statistical models had similar levels of variance (Figure 3B), the
choice of model when calculating relative titers is less important.
The PRNT evaluation point, however, is crucial to minimizing
variability, with a PRNT75 evaluation point up to 50% less
variable than alternatives (Figure 3B). Four-fold differences or
greater in titers are often used as evidence of seroconversion.
Using our variability estimates, we calculated the probability of
detecting a greater than four-fold difference in titers where there
was no difference in true titers (i.e., a false positive result). We
found that when a single set of dilutions is performed and a PRNT
evaluation point of PRNT75 is used, only 1.7% of assays would
falsely detect a greater than four-fold difference in titers compared
to 6.4% with a PRNT evaluation point of PRNT50 (Figure 5A).
Performing a single set of repeat dilutions on the same plate (but
with the acute and convalescent samples still performed on
separate plates) reduced the probability further, to 0.7%. Finally, if
both the acute and convalescent samples are on the same plate, the
probability of falsely detecting a greater than four-fold difference
in titer was 0.03%. Figure 5B sets out the 95% confidence intervals
Figure 4. (A) Variance in absolute titers by the number of
repeat sets of dilutions and where the repeats are performed
(either the same plate or on different plates). All titers estimated
using cloglog regression. (B) Observed titer variability. Each solid line
represents the 2.5% and 97.5% quantiles from the titers estimated from
the serum pool – virus combinations listed in Table 1. The shaded area
represents asymptotic 95% confidence intervals calculated using a
single variance estimate from all assays (represented by the yellow
circle in panel A).
doi:10.1371/journal.pntd.0002952.g004
Figure 5. (A) Probability of detecting a greater than four-fold
difference in titers between paired sera where no true
difference exists. All titers calculated through cloglog regres-
sion. (B) Example confidence intervals for the log difference between
titers calculated from paired sera (and the equivalent intervals for the
ratio) under different scenarios of PRNT evaluation points and where
repeat dilutions are performed.
doi:10.1371/journal.pntd.0002952.g005
Measuring Dengue Neutralization Titers
PLOS Neglected Tropical Diseases | www.plosntds.org 6 June 2014 | Volume 8 | Issue 6 | e2952
for different observed ratios: for example the 95% ratio for an
observed two-fold difference in titers using a PRNT evaluation
point of PRNT75 is 0.7–5.5 (equivalent to 0.360.4 on a log10
scale).
Multilevel model
To estimate the effects of experimental conditions on titers we
built a multilevel model incorporating the number of viral
passages, the cell type, reference well plaque count and the age
of the virus stock used in the experiments. We found that
passaging the virus in SM increased titers compared to LLC-MK2
cells (effect size of 1.15, 95% confidence interval of 1.09–1.21).
The total number of passages and the age of the viral stock at the
time of the experiment did not affect the titers. Higher plaque
counts in the reference well was associated with a very small
reduction in titers (effect size of 0.99, 95% confidence interval of
0.98–99). Less than 0.7% of the variability in PRNT50 estimates
could be explained by the model covariates, leaving over 99% of
variability unexplained (Table 3).
Discussion
Using repeated assays on the same serum sample with the same
viral strain, we estimated the extent to which measured PRNTs
vary. We found a consistent level of variability in titer estimates
across the viruses and serum pools used during the study period. A
measure of the variability of titers provides information on the
potential misclassification of individuals falling above or below any
specified PRNT evaluation point, information routinely used in
calculating sample sizes for a wide range of studies. By
characterizing the variability in measured titers, these findings
will aid in the determination of an individual’s immunity, the
design and interpretation of results from immunogenicity trials,
epidemiologic studies and allow the benchmarking of assays across
laboratories. Based on our findings, we set out a number of
recommendations for laboratories performing PRNTs (Box 1).
There have been a number of efforts to standardize the assay
[7,20–24]. A comprehensive effort by Roehrig et al., set out
guidelines for PRNTs, which were supported by the World Health
Organization [20,21]. Nevertheless, heterogeneities in approaches
between laboratories persist, particularly in PRNT evaluation
points, in large part because there had been no comprehensive
study of the variability in titers. The WHO recommends using a
PRNT50 titer for vaccinee sera and PRNT90 titers for epidemi-
ological studies. However, both vaccine and epidemiological
studies regularly use alternative PRNT evaluation points [6,10].
The stated benefit of the higher evaluation point is to decrease
variance while the stated benefit of the lower evaluation point is of
increased accuracy (i.e. reduced bias) [21]. We found that the
evaluation point with the lowest variance was actually between
PRNT75 and PRNT80 with little difference between the different
models used to calculate the titers. Bias, by contrast, differed
substantially by model with four-parameter non-linear regression
and cloglog largely unbiased across PRNT evaluation points
whereas probit and logit regression consistently over-estimated
titers. However, the choice of model only appeared important
where absolute titers were of interest as biases cancelled out in the
calculation of relative measures. Overall, we found that a PRNT
evaluation point of PRNT75 minimized the MSE between the
model PRNT estimates and our best estimate of the unbiased
PRNTs and should be used, where possible, across study types.
Lower PRNT evaluation points may remain preferable in the
estimation of low titers where the estimate at PRNT75 can be
regularly below the limit of detection (typically 1:10). However, the
biological meaningfulness of low PRNT titers is currently under
scrutiny. A recent dengue vaccine trial observed infections in
vaccinated individuals despite the apparent presence of detectable
titers [25]. These findings suggest that ‘some’ titers (e.g., greater
than 1:10) versus ‘no’ titers (e.g., less than 1:10) is insufficient to
differentiate between individuals with and without protective
immunity. Further research is urgently required to understand if
vaccines need to elicit higher titers than those generated by the
trial vaccine or if there exist qualitatively different markers of
protection (such as T-cell responses).
We found that around half of the variance in titers could be
explained through plate-specific factors, experimental condi-
tions that differ between plates but not within plates. In
particular, creating the viral preparations for each plate may be
an important contributor. Performing repeat dilutions on the
same plate cannot reduce plate-specific variance, as both
repeats will be perfectly correlated for these factors. This
explains why there was only a small reduction in variance in
titers calculated from repeat dilutions compared to the variance
from only single sets of dilutions (0.025 versus 0.032).
Performing repeats on separate plates would reduce this further
(we estimate to 0.016) and should be considered where precise
absolute titers are required. Where relative titers are calculated,
we estimated that the probability of observing four-fold
Table 3. Results of multilevel model for impact of experimental factors on PRNT75 estimates using cloglog regression.
Parameter Coefficient [95% CI]
Age of virus stock (yrs): mean: 2.2, sd: 1.0 1.00 [0.98–1.01]
# Plaques in reference well: mean: 32.6, sd: 7.1 0.99 [0.98–0.99]
Total # of passages: mean: 5.3, sd: 2.1 0.99 [0.98–1.00]
Cell passage:
- C6/36 and LLC-MK2 # experiments: 502 Ref
- C6/36 and SM # experiments: 1566 1.15 [1.09–1.21]
- Only C6/36 # experiments: 262 0.92 [0.06–15.2]
R2 (1) 0.006
(1) Marginal R2 that indicates the proportion of variance explained by the fixed effects only [31]. Model also adjusted for year of assay.
The model has a random intercept for the viral strain and serum pool used in the experiment and is also adjusted for the year of the assay. All coefficients have been
transformed by raising 10 to the power of the coefficient.
doi:10.1371/journal.pntd.0002952.t003
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differences in titers where it does not truly exist is less than one
per cent when a PRNT evaluation point of PRNT75 is used (it is
twice as high when a PRNT50 evaluation point is used). Our
findings indicate that the risk of a false positive detection of a
significant difference in titers is low even where a cut-off of a
three-fold difference in titers is used, especially where both the
acute and convalescent sera are placed on the same plate. It
remains unclear whether such titer differences are correlated
with immune protection or past exposure.
Laboratories may perform only two dilutions and use linear
interpolation to obtain PRNT estimates. We found that we could
only use half of the assays for this analysis, as the remaining
experiments would require unwise extrapolation outside the results
from the two dilutions. In these situations, laboratories need to
repeat the assays at wider dilution ranges. The substantial number
of experiments that could not be included in the analysis suggests
that performing only two dilutions may only have minimal
benefits. Single dilution neutralization tests only require a single
dilution, however, individual plaque reduction estimates had wide
confidence intervals: individuals with a true plaque reduction of
75% (and therefore should be scored as ‘positive’ in a SDNT using
an evaluation point of 70%) had 95% confidence intervals of
54%–96%, suggesting that many such individuals would be
wrongly characterized as negative [18,19]. This provides no
insight into the sensitivity or specificity of detecting exposure from
using an evaluation point of 70%.
The DENV-4 strain used in the assays was changed in 2009
resulting in a 11.4-fold increase in mean titers in the high serum
pool and a 12.1-fold increase in the low serum pool, confirming
previous findings of the importance of viral strain on titer estimates
[4]. The two DENV-4 strains come from two different genotypes
(the earlier strain was genotype 2 whereas the later one was
genotype 1). These findings highlight the possibility of vastly
different immunological response even within a single serotype.
Alongside the effect of viral strain, it has been suggested that the
number and cell type of viral passages could produce systematic
differences in PRNT estimates [4,7]. We found a small increase in
titers in experiments using viruses passaged through SM compared
to LLC-MK2 cells supporting similar previous findings [4]. The
total number of viral passages did not appear to impact PRNT
estimates, however, only small numbers of passages were
conducted (maximum of eight). Increasing this substantially or
only using mammalian cell lines such as Vero cells as
recommended by the WHO, may nevertheless impact estimates.
The presence of many overlapping plaques in a well may lead to
under-estimates in true plaque counts. However, we found only
negligible difference in titer estimates by the number of plaques in
the reference well, suggesting plaque overlap did not affect our
results. These findings suggest that the under-estimate in true
plaque counts was consistent across dilutions; alternatively, the
wells were sufficiently large and the plaque counts sufficiently small
to avoid substantial overlap. Laboratories using smaller wells may
nevertheless experience titer differences from differential levels of
plaque overlap by dilution. Overall, aside from viral strain,
experimental factors varied in our assays explained less than one
per cent of the observed variability in titer estimates. Experimental
factors that were held constant throughout our experiments, such
as incubation time and plaquing cell line, may nevertheless impact
titer estimates.
Our findings show that the assay is inherently variable. There
are many potential sources of variability in each experiment: (a)
the number of viral particles pipetted into each plate, (b) the extent
of viral–antibody interaction (c) the spatial arrangement of cells in
the monolayer and (d) the number of non-overlapping plaques
successfully generated and counted. While technicians can
minimize differences through effective mixing and careful
dilutions, there may be a limit to the extent that variability in
these factors can be reduced. The use of automated counting
methods that allow faster and more accurate particle counting
may help [26]. A related approach, the flow reduction neutral-
ization test that relies on immunofocus rather than cell death, may
produce less variable titer estimates [27]. In addition, flow-based
methods in laboratories with access to flow cytometry equipment
show some encouraging results, especially as these methods can
use human cells and allow for high-throughput of samples [26,28–
30]. Further work is needed to quantify the variability of these
alternative approaches.
The serum pools come from pooled human sera that contain a
wide range of antibodies not representative of a single individual’s
serum. Nevertheless, the ability for the pooled serum to neutralize
a single virus should remain constant. We were not able to explore
the biological significance of individual titers. In particular, the
significance of low titers for immune status remains unclear, as
does the serotype-specificity of the assay. PRNTs are used to
characterize infection parity, with high titers against two or more
serotypes considered suggestive of secondary infection. Future
research using sera of known infection status could shed light on
the specificity of such classifications. Further, serum with
neutralization titers outside the range used in this study may
perform differently. The range of titers in this study was wide
(PRNT75 range of 1:20–1:6000) and we observed a consistent
pattern in variability across this range. Nevertheless, naturally
occurring low titer antibodies (rather than the diluted high titer
Box 1. Recommendations for Performing and
Calculating Absolute and Relative PRNT Titers
Laboratory benchmarking
1. Perform repeated assays (,20) on same serum to
quantify lab-specific assay variability(a)
Absolute titers
1. Where possible, perform repeat dilutions on separate
plates with separate viral preparations
2. Calculate titers using cloglog regression at a PRNT
evaluation point of PRNT75
3. Report log-transformed titers with uncertainty estimates
calculated from benchmarking exercise
4. Report raw count data with dilutions in supplementary
materials
Relative titers
1. Where possible, place paired samples on same plate
2. Calculate individual titers at a PRNT evaluation point of
PRNT75 (choice of model is less important)
3. Report difference of log-transformed titers with uncer-
tainty estimates calculated from benchmarking exercise
4. Report raw count data with dilutions in supplementary
materials
(a) Where laboratories use identical sera as controls in each
assay, the variability in those titers could be used
instead.
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pools used here) may have different levels of avidity and affinity
that could impact titer variability. All viruses were passages
through C6/36 cells. Viruses solely passaged through mammalian
cells may be differently neutralized. We only used LLC-MK2
monolayers as plaquing cells. Other laboratories use different cell
lines (such as Vero cells, recommended by the WHO or BHK
cells), which may behave differently. However, it is unlikely that
the variability in titers would be markedly different. Laboratories
that use markedly different protocols may identify different
optimal PRNT evaluation points. These could be identified using
the methods presented here on repeated assays on the same sera.
In conclusion, providing uncertainty estimates with both
absolute and relative titer estimates would greatly aid the
interpretation of individual read-outs. While the estimates
provided here provide a first marker of the variance in the assay,
heterogeneities in variability between laboratories will exist. By
performing a small number of repeat assays (20 appears to be
sufficient to obtain a precise variance estimate) on the same serum
with the same virus on different plates, laboratories could generate
lab-specific variability estimates without requiring excessive
resources. Alternatively, where assays on identical control serum
are performed as routine, the variance in titers from these assays
could be calculated instead. Variance estimates could then be used
to calculate confidence intervals for all reported titers and allow
benchmarking of assay performance. This study demonstrates the
utility of raw results. Laboratories should consider reporting
plaque counts alongside titer estimates. This will allow investiga-
tors to easily compute alternative titers using different PRNT
evaluation points or statistical models, facilitating comparison
across laboratories. We also recommend that titers be reported on
a logarithmic scale (or log differences for relative titers) to allow
easy calculation and interpretation of confidence intervals.
Supporting Information
Data S1 Count data from all experiments.
(CSV)
Figure S1 Variance in titers between assays over different time
lags between the assays. All titers calculated using a PRNT
evaluation point of PRNT75 using cloglog regression from a single
set of dilutions.
(TIF)
Figure S2 Width of variance 95% confidence interval with
different numbers of repeated assays. Over 1,000 simulations
between 2 and 30 titers were randomly sampled from all the titers
(using cloglog regression at a PRNT evaluation point of PRNT75)
calculated from a randomly chosen viral strain – serum pool
combination from a single year. The variance between the titers
was then calculated. The line represents the width of the 95%
confidence interval calculated from the 2.5% and 97.5% quantiles
from the resultant distribution.
(TIF)
Figure S3 Variability in the bias in (A) PRNT50 using
conventional probit regression and (B) PRNT75 using cloglog
regression by titer (log10 scale). The red dots represent the mean
bias from each serum pool.
(TIF)
Text S1 Detailed methods.
(DOCX)
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